anti-LAG3-IL-2c

N/A

Report date: 2025/03/14 16:55:43

Base Information

Drug Nameanti-LAG3-IL-2c
Drug Alias Namedual LAG3 checkpoint inhibitor/IL-2 receptor agonist (Anwita Biosciences)
ClassificationBiologics
Mechanisms of ActionInterleukin-2 receptor agonistsLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 proteinInterleukin-2 receptor
Therapy Area/IndicationsSolid tumoursMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnwita Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnwita Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A